In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...

ZNTL stock gains as the FDA lifts clinical hold on studies of its lead candidate, azenosertib, which is being developed for different cancer indications.

study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC. The study is being conducted in partnership with ...

GSK has continued to beat my expectations as ... The company's oncology portfolio, consisting of Zejula, Blenrep, Jemperli, and Ojjaara/Omjjara, reported total sales of $450 million in the second ...

Shares of Zentalis Pharmaceuticals, Inc. ZNTL have plunged 71.7% in the past three months against the industry’s growth of 6.2%. The company is developing its lead product candidate, azenosertib ...

The phase I/II MAMMOTH (ZN-c3-006) study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC. The study is being ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

There's more to come in endometrial cancer as well, with RUBY Part 2 looking at the combination of Jemperli, chemo, and GSK's PARP inhibitor Zejula (niraparib), with results showing improved PFS ...